Farnesyl pyrophosphate synthase — Drug Target
All drugs that target Farnesyl pyrophosphate synthase — marketed and clinical-stage. Includes 5 drug classes acting on this target.
Drug classes
Bisphosphonate · incadronic acid · zoledronic acid · Vitamin D [EPC] · neridronic acid
Marketed (10)
- ZOL · Eisai Inc. · Bisphosphonate · Oncology, Bone Metabolism
ZOL (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. - Generic Zoledronic Acid · Cttq · Bisphosphonate · Oncology, Bone Metabolism
Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. - Bisphonal · Astellas Pharma · incadronic acid · Bone
- Zometa · Novartis · zoledronic acid · Oncology
Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity. - Aredia · Bisphosphonate · Oncology
- Fosamax · Merck And Co Inc · Vitamin D [EPC] · Bone
Fosamax works by inhibiting bone resorption, allowing bone density to increase. - Boniva · Hoffmann La Roche · Bisphosphonate · Bone
- Technescan Pyp · Oncology
- OST · Pharmbio Korea Co., Ltd. · Bisphosphonate · Osteoporosis
OST is an osteoclast inhibitor. - Zolendronic Acid · Wales Cancer Trials Unit · Bisphosphonate · Oncology, Bone Metabolism
Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Phase 3 pipeline (4)
- Neridronate · neridronic acid · Bone
Neridronate works by inhibiting the enzyme Farnesyl pyrophosphate synthase, which plays a crucial role in bone resorption. - Neridronate · Ente Ospedaliero Ospedali Galliera · Bone
- AXS-02 (oral zoledronate) · Axsome Therapeutics, Inc. · Bisphosphonate · Bone metabolism / Oncology
AXS-02 is an oral formulation of zoledronate, a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. - Minodronic acid hydrate · Ono Pharmaceutical Co. Ltd · Bisphosphonate · Bone metabolism / Osteoporosis
Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Phase 2 pipeline (1)
- Intravenous Infusion of Aclasta® · AUVA Traumazentrum Vienna Site UKH Meidling · Bisphosphonate · Oncology
Bisphosphonate that inhibits osteoclast-mediated bone resorption